Saccular intracranial aneurysms are balloon-like dilations of the intracranial arterial wall; their hemorrhage commonly results in severe neurologic impairment and death. We report a second genome-wide association study with discovery and replication cohorts from Europe and Japan comprising 5,891 cases and 14,181 controls with ~832,000 genotyped and imputed SNPs across discovery cohorts. We identified three new loci showing strong evidence for association with intracranial aneurysms in the combined dataset, including intervals near RBBP8 on 18q11.2 (odds ratio (OR) = 1.22, P = 1.1 × 10 −12 ), STARD13-KL on 13q13.1 (OR = 1.20, P = 2.5 × 10 −9 ) and a gene-rich region on 10q24.32 (OR = 1.29, P = 1.2 × 10 −9 ). We also confirmed prior associations near SOX17 (8q11.23-q12.1; OR = 1.28, P = 1.3 × 10 −12 ) and CDKN2A-CDKN2B (9p21.3; OR = 1.31, P = 1.5 × 10 −22 ). It is noteworthy that several putative risk genes play a role in cell-cycle progression, potentially affecting the proliferation and senescence of progenitor-cell populations that are responsible for vascular formation and repair.
l e t t e r s
Saccular intracranial aneurysms are balloon-like dilations of the intracranial arterial wall; their hemorrhage commonly results in severe neurologic impairment and death. We report a second genome-wide association study with discovery and replication cohorts from Europe and Japan comprising 5,891 cases and 14,181 controls with ~832,000 genotyped and imputed SNPs across discovery cohorts. We identified three new loci showing strong evidence for association with intracranial aneurysms in the combined dataset, including intervals near RBBP8 on 18q11.2 (odds ratio (OR) = 1.22, P = 1.1 × 10 −12 ), STARD13-KL on 13q13.1 (OR = 1.20, P = 2.5 × 10 −9 ) and a gene-rich region on 10q24.32 (OR = 1.29, P = 1.2 × 10 −9 ). We also confirmed prior associations near SOX17 (8q11.23-q12.1; OR = 1.28, P = 1.3 × 10 −12 ) and CDKN2A-CDKN2B (9p21.3; OR = 1.31, P = 1.5 × 10 −22 ). It is noteworthy that several putative risk genes play a role in cell-cycle progression, potentially affecting the proliferation and senescence of progenitor-cell populations that are responsible for vascular formation and repair.
Intracranial aneurysms affect approximately 2% of the general population and arise from the action of multiple genetic and environmental risk factors 1 . We previously reported the first genome-wide association study (GWAS) of intracranial aneurysms 2 that identified three risk loci on chromosomes 8q11.23-q12.1, 9p21.3 and 2q33.1 with P < 5 × 10 −8 .
This previous study had limited power to detect loci imparting genotypic relative risk (GRR) <1. 35 Table 1) .
(Supplementary
To increase the power to detect additional loci of similar or smaller effect, we ascertained and whole-genome genotyped two new European case cohorts (n = 1,616) and collected genotyping data from five additional European control cohorts (Supplementary Note, n = 11,955). We also increased the size of the original Japanese replication cohort and added a new one (2,282 affected individuals (cases) and 905 controls) ( Table 1 ). The new combined cohort had nearly threefold more cases than the original cohort and increased our power to detect variants with modest effect sizes. For example, this study had 89% and 64% average power to detect common variants (minor allele frequencies (MAF) ≥ 10%) with GRR of 1.25 and 1.20, respectively (Supplementary Table 1 ).
All subjects were genotyped using the Illumina platform. The new as well as the previously analyzed genotyping data were subjected to well-established quality-control measures (Supplementary Table 2) . We sought to eliminate potential confounding due to population stratification and gender 1, 3 by matching cases and controls of the same gender based on inferred genetic ancestry. As previous studies demonstrated that the Finnish population forms an ancestry cluster distinct from other European populations similar to those included in this study 4, 5 , we analyzed our Finnish cohort independently from the others. To maximize opportunities for genetic matching and analytic power, we analyzed all subjects in the remaining European cohorts together. The resulting matched case-control data consisted of 808 cases and l e t t e r s 4 ,393 controls in the Finnish cohort and 1,972 cases and 8,122 controls in the rest of the combined European cohort (Supplementary Table 3) . We used the genotype data that passed quality-control filters and phased chromosomes from the HapMap CEU sample to impute missing genotypes 6 . We based our further analyses on 831,534 SNPs that passed the quality-control filters both in the Finnish and European samples ( Table 1 and Supplementary Table 2) .
We tested for association of each quality control-passed SNP with intracranial aneurysms using conditional logistic regression, assuming a log-additive effect of allele dosage. We corrected each cohort for residual overdispersion (Table 1) using genomic control 7 and combined the results from the Finnish and European cohorts to obtain P values, ORs and CIs for the discovery cohort of 2,780 cases and 12,515 controls using a fixed-effects model.
To evaluate the strength of association, in addition to obtaining P values, we employed a Bayesian approach 8 . We used the Bayes factor that represents the fold-change of the odds of association before and after observing the data 9 and the posterior probability of association (PPA), calculated through the Bayes factor, that provides a simple probabilistic measure of the evidence of association 8, 10 . For every SNP, we assumed a uniform prior probability of association of 1/10,000 and set the prior of the logarithm of the per-allele OR as a normal distribution with a 95% probability for the OR to be between 0.67 and 1.5, with larger weights for smaller effect sizes 9, 11 .
From the discovery results, we eliminated two imputed SNPs that showed PPAs of 0.97 and 0.94 because their association signals were not supported by surrounding genotyped SNPs and because their genotypes were not confirmed by direct genotyping results (data not shown). This resulted in 831,532 SNPs that passed quality control (Supplementary Table 2) .
We observed three regions that showed very high PPAs (>0.995; Fig. 1a) and also a substantial excess of SNPs with P < 1 × 10 −3 (1, 295 SNPs versus 831 SNPs expected by chance) even after excluding those within previously identified associated regions 2 (Fig. 1b) . Moreover, we observed a strong correlation between the P values and Bayes factors for the upper tail of the distribution (Fig. 1c) .
We focused on five genomic regions (Fig. 1a) that contained at least one SNP with PPA >0.5 for which the hypothesis of association with intracranial aneurysm was more likely than the null hypothesis of no association. The PPAs of the most highly associated SNPs in these intervals ranged from 0.6621 to >0.9999 and the P values ranged from 7.9 × 10 −7 to 2.2 × 10 −16 (Supplementary Table 4 ). The five chromosomal segments included three newly identified SNP clusters on 10q24.32, 13q13.1 and 18q11.2. The remaining two regions were previously identified loci on 8q11.23-q12.1 and 9p21.3 ( Fig. 2;  ref. 2). The third locus identified in our previous study, on 2q33, did not contain any SNPs with PPA >0.5. Furthermore, consistent with our previous results 2 , detailed analysis of the 8q11.23-q12.1 region detected two independent association signals within the <100-kb interval that spans the SOX17 locus ( Fig. 2 and Supplementary  Fig. 1) ; these two signals are hereafter referred to as 5′-SOX17 and 3′-SOX17. Thus, the five chromosomal segments comprised six independent association signals for follow-up.
We performed replication genotyping in two Japanese cohorts including 3,111 cases and 1,666 controls (JP1 and JP2, see Table 1 ). For each independent signal, we selected for replication the genotyped SNP with the highest PPA and added up to two additional SNPs per locus. For the 5′-SOX17 region, we selected two SNPs analyzed previously, as they tag the most significant SNP in the current study (Supplementary Fig. 1 ). 
l e t t e r s
All but one of the SNPs (rs12411886 on 10q24.32 in JP1) were successfully genotyped and passed quality-control filters. We tested for association of each SNP with intracranial aneurysm using logistic regression stratified by gender, specifying the same model as for the discovery cohort (Supplementary Table 5 ). We combined results from JP1 and JP2 using a fixed-effects model ( Table 2 and  Supplementary Table 4) . We considered an association to be replicated if the Bayes factor increased the odds of association more than tenfold after the replication data was observed.
Of the six candidate loci, all but the 5′-SOX17 interval were replicated, with replication P values ranging from 0.0019 to 1.0 × 10 −7 , and the odds of association with intracranial aneurysm increasing by 22.9-fold to 1.5 × 10 5 -fold, yielding robust evidence for replication for each interval ( Table 2) .
We combined the discovery and replication results using a fixedeffects model. All of the five loci that replicated in the Japanese cohort surpassed the conventional threshold for genome-wide significance (P < 5 × 10 −8 ), with P values ranging from 2.5 × 10 −9 to 1.5 × 10 −22 , and all also had PPAs ≥ 0.998 ( Table 2) .
In order to determine each cohort's contribution to the observed association and to assess the consistency of the effect size across groups, we analyzed each of them separately ( Table 1  and Supplementary Table 5 ) and then combined the results from the six cohorts using a random-effects model. The association results remained highly significant (Fig. 3) . For the five loci that were replicated in the Japanese cohorts, we found no evidence of significant heterogeneity (P > 0.1). Every cohort had the same risk allele and provided support for association with the exception of the JP1 sample for the 3′-SOX17 locus, consistent with our previous study 2 (Fig. 3) .
The most significant association was detected in the previously reported 2 9p21.3 region near CDKN2A and CDKN2B with P = 1.5 × 10 −22 (OR = 1.32, PPA > 0.9999). All of the newly studied cohorts strongly supported this association with intracranial aneurysm (Fig. 3) . The same allele is associated with coronary artery disease but not with type 2 diabetes 12 . Similarly, the previously reported 8q11.23-q12.1 region showed significant association. The 3′-SOX17 interval (rs92986506) showed robust association with P = 1.3 × 10 −12 (OR = 1.28, PPA > 0.9999) and all new cohorts supported the association of this SNP with intracranial aneurysm (Fig. 3) . For the 5′-SOX17 region (rs10958409), the new cohorts introduced a substantial heterogeneity, lowering the PPA to 0.016 (Fig. 3) .
Among the newly identified loci, the strongest association was found at rs11661542 on 18q11.2 (OR = 1.22, P = 1.1 × 10 −12 , PPA > 0.9999). A cluster of SNPs that is associated with intracranial aneurysm spans the interval between 18.400 Mb and 18.509 Mb and is strongly correlated with rs11661542 (Fig. 2) . A single gene, RBBP8 (encoding the retinoblastoma binding protein 8), is located within an extended linkage disequilibrium interval (Fig. 2) .
The second strongest new association was at rs12413409 on 10q24.32 (OR = 1.29, P = 1.2 × 10 −9 , PPA = 0.9990), which maps to intron 1 of CNNM2 (encoding cyclin M2) (Fig. 2) . A cluster of SNPs that are strongly correlated with rs12413409 and are located within a ~247-kb interval in the same linkage disequilibrium block supported the association (Fig. 2) .
The third new locus is defined by rs9315204 at 13q13.1 (OR = 1.20, P = 2.5 × 10 −9 , PPA = 0.9981) in intron 7 of STARD13 (encoding the StAR-related lipid transfer (START) domain containing 13) (Fig. 2) . Two SNPs, rs1980781 and rs3742321, that are strongly correlated with rs9315204 (r 2 > 0.9) also showed significant association with intracranial aneurysm (Fig. 2 and Supplementary  Table 4 ). These two SNPs are missense (lysine to arginine) and synonymous coding variants of STARD13, respectively. Another gene that has been implicated in aging phenotypes, KL (encoding klotho), is located nearby 13 . 
A search of the gene-expression database (eQTL browser, see URLs) for all the intracranial aneurysm-risk loci did not reveal any consistent pattern of association of intracranial aneurysm SNPs with variation in gene expression levels.
In this second GWAS of intracranial aneurysm, which included nearly three times as many cases as the initial study, we detected three new risk loci and obtained strong independent evidence for association of two previously identified loci. The evidence that these are 
1.12
Odds ratio (log scale)
Odds ratio (log scale) Odds ratio (log scale)
Odds ratio (log scale) Diamonds represent the summary OR estimates and 95% CIs for the meta-analyses of six cohorts (using fixed-and random-effects models). Log 10 (Bayes factor) > 0 supports association with intracranial aneurysm, whereas log 10 (Bayes factor) < 0 supports no association with intracranial aneurysm. Analyzing the results here as six distinct cohorts rather than four cohorts (as in the primary analysis) resulted in only minor differences due to different weights given to sub-cohorts of the combined European cohort.
l e t t e r s bona fide risk loci for intracranial aneurysm is very strong from both Bayesian measures and conventional P values. Given our power (~90%) to detect variants that confer risk of intracranial aneurysm with GRR = 1.25 and MAFs ≥ 10%, we expect that we have identified most of these variants, limited principally by potential gaps in SNP coverage. Indeed, across the rest of the genome, there was no locus with PPA >0.22 and MAF ≥10%, whereas there were 14 loci with PPAs between 0.1 and 0.22 and ORs between 1.16 and 1.25 (data not shown). We expect that a fraction of these loci are genuine intracranial aneurysm risk loci, as suggested by the excess of SNPs with P < 1 × 10 -3 (Fig. 1b) ; exploring this possibility will require analysis of larger intracranial aneurysm cohorts and/or genotyping of alleles with lower MAFs.
Based on the results of the first GWAS of intracranial aneurysm and the role of the implicated gene products, Sox17 and p15 INK4b -p16 INK4a , we previously hypothesized 2 that the genes associated with intracranial aneurysm might play a role in determining cell cycle progression and may affect the proliferation 14 and senescence of progenitor-cell populations and/or the balance between production of progenitor cells versus cells committed to differentiation. Genes located within the newly identified regions support this idea. The protein encoded by RBBP8, located within the 18q11.2 region, influences progression through the cell cycle by interacting with BRCA1 15 . Similarly, of the two genes located within the 13q13.1 interval, STARD13 contains the Rho-GAP and C-terminal STAR-related lipid transfer (START) domains and its overexpression results in suppression of cell proliferation 16 . The other gene implicated here, KL, encodes a transmembrane protein that modulates FGF receptor specificity 17 ; mice lacking KL show accelerated aging in diverse organ systems 13 .
On the assumption that there is a fourfold increase in the risk of intracranial aneurysm among siblings of cases 18, 19 and that the SNPs combine to increase log-odds of disease in an additive fashion, the five intracranial aneurysm risk loci explain 5.2% (within the Finnish cohort), 4.0% (in the European cohort) and 3.5% (in the combined JP1 and JP2 cohort) of the familial risk of intracranial aneurysm. Under this model, the odds of developing an intracranial aneurysm varies 4.99-to 7.63-fold across the top and bottom 1% of genetic risk profiles at these loci in the populations studied here and 3.61-to 4.64-fold across the 5% extremes (Supplementary Fig. 2 ). When combined with traditional risk factors such as gender, blood pressure and smoking, these findings form the basis of future work aimed at preclinical identification of individuals who are at high risk of intracranial aneurysm formation and rupture.
URLs. eQTL browser, http://eqtl.uchicago.edu/.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
ONLINE MEthOdS
Genotyping. Whole-genome genotyping for the discovery cohort was performed on the Illumina platform according to the manufacturer's protocol (Illumina). Beadchips used for individual cohorts are presented in Supplementary Table 2 . Replication genotyping in the JP1 cohort was performed using either Taqman (Applied Biosystems) or MassARRAY (Sequenom) assays. For the JP2 cohort, genotyping for cases was performed using the multiplex PCR-based Invader assay (Third Wave Technologies Inc.); genotyping for controls was performed on an Illumina platform as described previously 20 .
Ethics. The study protocol was approved by the Yale Human Investigation Committee (HIC protocol #7680). Institutional review board approval for genetic studies, along with written consent from all study participants, was obtained at all participating institutions.
Data storage and analysis tools. We used PLINK 21 v1.06 and R statistical environment v2.9.0 (in particular, the snpMatrix package 22 ) for storage of genotype data and data analysis.
Preprocessing. Prior to the analysis of genotyping data, we excluded SNPs that were located either on mitochondrial DNA or sex chromosomes, SNPs with A/T or C/G alleles, those for which all subjects were assigned as 'no call', and those that were assayed on Hap300v1 or 550v1 but were dropped from newer versions.
Sample quality control. We excluded subjects in the discovery cohort who did not conform to our study design on the basis of genotyping and information quality, cryptic relatedness and population outliers. We summarize the sample exclusion steps in Supplementary Table 2 . This filtering process resulted in the inclusion of 835 cases and 6,529 controls in the Finnish cohort and 2,000 cases and 8,722 controls in the rest of the combined European cohort.
Imputation.
We performed imputation analysis with the HapMap phase II CEU reference panel (release 24) using the IMPUTE v1 software 6 . The analysis was performed separately for the Finnish and European cohorts. We converted posterior probabilities of three possible genotypes to fractional allele dosage scores (between 0 and 2) and used these scores for association tests in order to take into account the imputation uncertainty 23 . For the quality assessment of imputed SNPs, we also converted the posterior probabilities to the most likely genotypes with the threshold at 0.9.
Case-control matching. Population stratification and independent genotyping of cases and controls are major causes of confounding in GWAS 24 . Because our study consisted of multiple independently ascertained cohorts that were genotyped separately, we performed a stringent analysis to control for these biases by inferring the genetic ancestries of subjects 25, 26 . We used the Laplacian eigenmaps 27 to infer population structure. Following the determination of the number of dimensions (K + 1) using the threshold given in Lee et al. 28 , we used the K-dimensional nontrivial generalized eigenvectors 29 to calculate the Euclidean distance between any two subjects.
In the course of this analysis, we excluded 'isolated' subjects who were identified by using the nearest-neighbor distance distributions in any of the two-dimensional sections. After excluding these subjects, we observed 13 dimensions in the Finnish cohort and 5 dimensions in the European cohort. The larger dimensions observed in the Finnish sample could be attributable to the presence of many isolated populations in Finland 5 .
Before matching, we stratified data into males and females because female gender is a known risk factor of intracranial aneurysm 1, 3 . We also set the maximum distance between cases and controls to match to be less than 0.028 in the Finnish cohort and 0.009 in the European cohort. These values were determined by examining the distribution of the nearest-neighbor distances in K dimensions (data not shown). We matched cases and controls using the fullmatch function in the R-package optmatch 30, 31 . SNP quality control. For both genotyped and imputed SNPs in the discovery cohort, we applied quality-control filters to individual cohorts and to cases and controls separately on the basis of the missing rate, MAF and the P value of the exact test of Hardy-Weinberg equilibrium 32 . For imputed SNPs, we also assessed imputation quality using the average posterior probability, MAF and allelic R 2 metric 33 . Finally, we assessed differential missingness between cases and controls (Supplementary Table 2 ).
Any genotyped SNP that passed the quality-control filters both in the European and Finnish cohorts was referred to as a 'genotyped SNP', and any one for which we used the quality control-passed imputation data either in one or both of the cohorts was classified as an 'imputed SNP'.
For genotyping data of the replication cohorts, we excluded SNPs if any of the following three conditions were met in either cases or controls: (i) missing rate >0.05; (ii) P value of the exact test of Hardy-Weinberg equilibrium <0.001; or (iii) MAF <0.01.
Statistical analysis.
Cohort-wise association analysis. We tested for association between each quality control-passed SNP and intracranial aneurysm using conditional and unconditional logistic regression for the discovery and replication cohorts, respectively 34 . For the discovery cohort, we used the matched strata to correct for potential confounding due to population stratification and gender, and for the replication cohorts we adjusted for gender. We assumed the log-additive effect of allele dosage on disease risk. We obtained P values from the score test (two-sided) and estimated the logarithm of per-allele ORs with standard errors by maximizing the conditional or unconditional likelihood. Both the test statistic and the standard error of the log of the OR were corrected using genomic control 7 . We performed the association analysis for the Finnish and European cohorts, as well as subcohorts of the European group that consisted of NL cases, DE cases or @neurIST cases and their matched controls ( Table 1 and Supplementary Table 3) . We used the following R functions to perform the association analysis: clogit, glm and snp.rhs.tests 22 .
Meta-analysis. We combined the cohort-wise per-allele ORs in the Finnish and European cohorts using a fixed-effects model of meta-analysis for 831,534 quality control-passed SNPs to obtain the discovery results. For SNPs analyzed both in the discovery and replication cohorts, we combined JP1 and JP2 to obtain replication results and all four cohorts to obtain combined results. Our primary analysis was based on the fixed-effects model 23 . To assess the heterogeneity of the effect size between cohorts, we first divided the European cohort into three groups as described above, aiming to analyze the data without averaging effect sizes over the combined European cohorts and then combined our six cohorts using the random-effects model. We employed the restricted maximum likelihood procedure to estimate the between-cohort heterogeneity variance (τ 2 ) using the R function MiMa 35 (see URLs). From this estimate, we calculated the Cochran's Q statistic and the I 2 statistic (the percentage of variation across studies that is due to heterogeneity rather than chance) 36 .
Bayesian evaluation of the strength of association. To evaluate the strength of association with intracranial aneurysm, we used a Bayesian approach 9, 37 . A limitation of the use of P values alone is that variability in factors such as effect size, MAF and sample size can result in identical statistics that might correspond to markedly different levels of evidence regarding the strength of association 10 . The Bayes factor provides an alternative that compares the probabilities of the data under the alternative hypothesis of association versus the null hypothesis of no association. For computational simplicity, we approximated the Bayes factor as described by Wakefield 8 . For all SNPs, we assumed the same prior distribution for the log-OR: a normal distribution with a mean of 0 and a standard deviation of log(1.5)/Φ −1 (0.975), where Φ is the normal distribution function 9 .
The PPA 10 provides a simple probabilistic measure of evidence by introducing the prior probability of association, π 1 . We assumed a uniform prior, π 1 = 1/10,000, for all the SNPs 11 . For Bayes factor >10 6 , changing π 1 to a more conservative value of 1/100,000 would result in little change in the PPA.
To combine the results from multiple cohorts, we extended the formula 38 to be applicable to multiple (>2) cohorts.
Conditional analysis. For each region that contained a SNP with PPA >0.5, we examined the number of independent association signals by testing for association of every genotyped SNP with intracranial aneurysm by adjusting for the effect of a specified SNP (Supplementary Fig. 1) .
Two-locus interaction analysis. We tested for deviation from a linear model, which assumes that two SNPs combine to increase the log-odds of disease in
